Get the Stockscreener App
32.88
0.74%
0.24
After Hours:
32.88
Royalty Pharma Plc stock is traded at $32.88, with a volume of 11.68M.
It is up +0.74% in the last 24 hours and up +0.52% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$32.64
Open:
$32.64
24h Volume:
11.68M
Relative Volume:
2.69
Market Cap:
$13.85B
Revenue:
$2.26B
Net Income/Loss:
$1.09B
P/E Ratio:
14.03
EPS:
2.3431
Net Cash Flow:
$2.70B
1W Performance:
+1.33%
1M Performance:
+0.52%
6M Performance:
+23.33%
1Y Performance:
+24.59%
1-Day Range:
$32.29
$33.11
1-Week Range:
$32.21
$33.11
52-Week Range:
$24.05
$34.31
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.88 | 13.67B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by California State Teachers Retirement System - MarketBeat
Mackenzie Financial Corp Buys 9,313 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Position Trimmed by Tidal Investments LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
111 Capital Purchases New Shares in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Lansforsakringar Fondforvaltning AB publ Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
GF Fund Management CO. LTD. Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Squarepoint Ops LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Janus Henderson Group PLC Decreases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
University of Texas Texas AM Investment Management Co. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Nuveen Asset Management LLC Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Worldquant Millennium Advisors LLC Has $15.57 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
State of Wyoming Has $385,000 Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Captrust Financial Advisors Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Investments LP Has $61.74 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Point72 Asset Management L.P. - MarketBeat
USS Investment Management Ltd Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Quantinno Capital Management LP - MarketBeat
Raiffeisen Bank International AG Makes New $506,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Advisers LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma - insights.citeline.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Man Group plc - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Ethic Inc. - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Trimmed by OMERS ADMINISTRATION Corp - MarketBeat
Royalty Pharma at RBC Capital Markets: Strategic Funding Insights By Investing.com - Investing.com Nigeria
Transcript : Royalty Pharma plc Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 04 - marketscreener.com
Occudo Quantitative Strategies LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
RPRX Stock Performance Following Recent Offering Details | RPRX - GuruFocus
Royalty Pharma plc (NASDAQ:RPRX) Holdings Trimmed by Captrust Financial Advisors - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Receives $42.50 Consensus PT from Analysts - Defense World
Patient Capital Management LLC Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma completes major acquisition By Investing.com - Investing.com Canada
Royalty Pharma completes major acquisition - Investing.com
Balyasny Asset Management L.P. Purchases Shares of 59,755 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Bank of America Corp DE - MarketBeat
Royalty Pharma Completes RP Management Acquisition - citybiz
Baird Financial Group Inc. Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):